US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Crinetics Pharmaceuticals, Inc.
< Previous
1
2
3
4
Next >
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 03, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
June 30, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
June 14, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
June 14, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
June 02, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
June 02, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
May 22, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
May 07, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
April 27, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
March 26, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 26, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
February 05, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
January 26, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
January 22, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
January 06, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
January 05, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
January 05, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
January 04, 2026
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
December 18, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
December 11, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
December 03, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
November 20, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 06, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
October 23, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
October 06, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
September 25, 2025
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
CRNX
< Previous
1
2
3
4
Next >
